profit from every £100 of sales.
£0£100
Dr. Martens
£0.54-14.67% today
-43.1% in 1 year
1-year low £0.541-year high £0.95
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay £21.76 for every £1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Dr. Martens sold, what it kept, and what it did with the cash.
Sales went from £1.00 billion in 2023 to £765 million in 2026, with £23.8 million of profit last year.
SalesProfit
Dr. Martens handed back 24% of the cash it generated last year.
£25M
Free cash flow 2026£131M
Bought back its own shares£7M
Paid as dividends£25M
Cash vs. debt£180M vs. £394M
Dr. Martens vs. similar companies
Dr. Martens grows the slowest of these 5 and is priced in the middle for its profits.
| Company | Profit from £100 of sales | Sales growth a year | Price per £1 of profit |
|---|---|---|---|
| Dr. Martens | 21.8× · Fair price | ||
 Nike | 18.0× · Fair price | ||
 Adidas | 22.3× · Fair price | ||
 ASICS | 34.8× · Expensive | ||
 Zhejiang China Commodities City Group | 15.6× · Fair price |
AI analysis
An AI analyst reads Dr. Martens's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of GBP | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 1,000 | 877 | 788 | 765 | |
| 618 | 575 | 512 | 506 | |
| 191 | 128 | 44 | 60 | |
| 235 | 196 | 111 | 128 | |
| 129 | 69 | 5 | 24 | |
| 0.13 | 0.07 | 0.01 | 0.02 | |
| 61.8% | 65.6% | 65.0% | 66.2% | |
| 19.1% | 14.6% | 5.6% | 7.9% | |
| 12.9% | 7.9% | 0.6% | 3.1% |
Balance sheet
| In millions of GBP | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 993 | 952 | 890 | 877 |
| Cash | 158 | 111 | 156 | 180 |
| Total debt | 446 | 477 | 404 | 394 |
| Total liabilities | 588 | 584 | 523 | 516 |
| 404 | 368 | 366 | 362 | |
| 1,001 | 986 | 974 | 980 | |
| 15.6% | 11.0% | 3.7% | 5.9% | |
| 31.9% | 18.8% | 1.2% | 6.6% |
Cash flow
| In millions of GBP | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 73 | 168 | 196 | 143 | |
| 51 | 28 | 19 | 12 | |
| 21 | 140 | 178 | 131 | |
| Dividends paid | 58 | 58 | 10 | 25 |
| 0 | 51 | 0 | 7 | |
| 1 | 4 | 7 | 5 |
Valuation
- 21.8×
- –
- –
- 1.9×
- 0.7×
- 4.0×
- 5.7×
- 25.3%
- 4.6%
- 4.8%
Profitability
- 66.2%
- 7.9%
- 3.1%
- –
- 5.9%
- 9.1%
- –
- –
- –
- –
Growth
- −8.6%
- −42.9%
- –
- –
- −0.7%
Financial health
- 1.7×
- 1.09
- –
- 2.2×
- 2.61
- –
- –
How it ranks in Consumer Discretionary
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 37%of 977
Bottom 48%of 992
Bottom 46%of 856
Bottom 5%of 993
Top 4%of 980
4.8%of the share price, paid each year
On $1,000 invested$48a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
103.4% of its profit
Room to growStretchedMore than it earns: 18.8%
News
Doximity (DOCS) Registers a Bigger Fall Than the Market: Important Facts to NoteYahoo Finance · Sep 15, 2026The newest story we have is from Sep 15, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
54No pass
Benjamin Graham
66Pass
Philip Fisher
45No pass
Peter Lynch
17No pass
Joel Greenblatt
37No pass
Charlie Munger
39No pass
Terry Smith
38No pass
Questions about Dr. Martens
Is Dr. Martens a good stock to buy?
A business with weak numbers at a fair price. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Dr. Martens AI analysis
What does Dr. Martens do?
Dr. Martens plc engages in the design, development, procurement, marketing, sale, and distribution of footwear. The company sells its footwear under the Dr. Martens brand name in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Dr. It is in Footwear & Accessories, based in London, United Kingdom, with 2,377 employees.
Does Dr. Martens pay a dividend?
Yes. At today's price the dividend is 4.8% a year, about 103% of its yearly profit. In 2026 it paid out £24.6 million in dividends.
Is Dr. Martens stock halal?
No. Dr. Martens does not pass our halal screen: its debt is 76% of its market value, at or above the 33% limit. How we check
How has Dr. Martens stock done over the past year?
Down 43.1% over the past twelve months, to £0.54. It traded between £0.54 and £0.95 and is 43.1% below its high.
Who are Dr. Martens's competitors?
The largest listed companies in the same industry are Nike, Adidas, ASICS and Zhejiang China Commodities City Group. The peers table on this page compares their profit, growth and price with Dr. Martens's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.